Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 25
Filter
1.
Circulation ; 145(2): 110-121, 2022 01 11.
Article in English | MEDLINE | ID: mdl-34743555

ABSTRACT

BACKGROUND: Socioeconomic disadvantage is a strong determinant of adverse outcomes in patients with heart failure. However, the contribution of community-level economic distress to adverse outcomes in heart failure may differ across races and ethnicities. METHODS: Patients of self-reported Black, White, and Hispanic race and ethnicity hospitalized with heart failure between 2014 and 2019 were identified from the Medicare MedPAR Part A 100% Files. We used patient-level residential ZIP code to quantify community-level economic distress on the basis of the Distressed Community Index (quintile 5: economically distressed versus quintiles 1-4: nondistressed). The association of continuous and categorical measures (distressed versus nondistressed) of Distressed Community Index with 30-day, 6-month, and 1-year risk-adjusted mortality, readmission burden, and home time were assessed separately by race and ethnicity groups. RESULTS: The study included 1 611 586 White (13.2% economically distressed), 205 840 Black (50.6% economically distressed), and 89 199 Hispanic (27.3% economically distressed) patients. Among White patients, living in economically distressed (versus nondistressed) communities was significantly associated with a higher risk of adverse outcomes at 30-day and 1-year follow-up. Among Black and Hispanic patients, the risk of adverse outcomes associated with living in distressed versus nondistressed communities was not meaningfully different at 30 days and became more prominent by 1-year follow-up. Similarly, in the restricted cubic spline analysis, a stronger and more graded association was observed between Distressed Community Index score and risk of adverse outcomes in White patients (versus Black and Hispanic patients). Furthermore, the association between community-level economic distress and risk of adverse outcomes for Black patients differed in rural versus urban areas. Living in economically distressed communities was significantly associated with a higher risk of mortality and lower home time at 1-year follow-up in rural areas but not urban areas. CONCLUSIONS: The association between community-level economic distress and risk of adverse outcomes differs across race and ethnic groups, with a stronger association noted in White patients at short- and long-term follow-up. Among Black patients, the association of community-level economic distress with a higher risk of adverse outcomes is less evident in the short term and is more robust and significant in the long-term follow-up and rural areas.


Subject(s)
Heart Failure/complications , Heart Failure/epidemiology , Long Term Adverse Effects/pathology , Aged , Aged, 80 and over , Female , Hospitalization , Humans , Male , Medicare , Race Factors , United States
2.
J Am Coll Cardiol ; 78(18): 1782-1795, 2021 11 02.
Article in English | MEDLINE | ID: mdl-34711337

ABSTRACT

BACKGROUND: The effects of nonphysiological flow generated by continuous-flow (CF) left ventricular assist devices (LVADs) on the aorta remain poorly understood. OBJECTIVES: The authors sought to quantify indexes of fibrosis and determine the molecular signature of post-CF-LVAD vascular remodeling. METHODS: Paired aortic tissue was collected at CF-LVAD implant and subsequently at transplant from 22 patients. Aortic wall morphometry and fibrillar collagen content (a measure of fibrosis) was quantified. In addition, whole-transcriptome profiling by RNA sequencing and follow-up immunohistochemistry were performed to evaluate CF-LVAD-mediated changes in aortic mRNA and protein expression. RESULTS: The mean age was 52 ± 12 years, with a mean duration of CF-LVAD of 224 ± 193 days (range 45-798 days). There was a significant increase in the thickness of the collagen-rich adventitial layer from 218 ± 110 µm pre-LVAD to 410 ± 209 µm post-LVAD (P < 0.01). Furthermore, there was an increase in intimal and medial mean fibrillar collagen intensity from 22 ± 11 a.u. pre-LVAD to 41 ± 24 a.u. post-LVAD (P < 0.0001). The magnitude of this increase in fibrosis was greater among patients with longer durations of CF-LVAD support. CF-LVAD led to profound down-regulation in expression of extracellular matrix-degrading enzymes, such as matrix metalloproteinase-19 and ADAMTS4, whereas no evidence of fibroblast activation was noted. CONCLUSIONS: There is aortic remodeling and fibrosis after CF-LVAD that correlates with the duration of support. This fibrosis is due, at least in part, to suppression of extracellular matrix-degrading enzyme expression. Further research is needed to examine the contribution of nonphysiological flow patterns on vascular function and whether modulation of pulsatility may improve vascular remodeling and long-term outcomes.


Subject(s)
Aortic Diseases , Assisted Circulation , Extracellular Matrix/enzymology , Heart Failure/therapy , Heart-Assist Devices/adverse effects , ADAMTS4 Protein/metabolism , Aortic Diseases/etiology , Aortic Diseases/pathology , Aortic Diseases/physiopathology , Assisted Circulation/adverse effects , Assisted Circulation/instrumentation , Assisted Circulation/methods , Female , Fibrosis , Humans , Immunohistochemistry , Long Term Adverse Effects/pathology , Male , Matrix Metalloproteinases, Secreted/metabolism , Middle Aged , Sequence Analysis, RNA/methods , Vascular Remodeling/physiology
3.
Heart Rhythm ; 18(12): 2101-2109, 2021 12.
Article in English | MEDLINE | ID: mdl-34461305

ABSTRACT

BACKGROUND: Leadless pacemakers (LPs) have proven safe and effective, but device revisions remain necessary. Either replacing the LP or implanting a new adjacent LP is feasible. Replacement seems more appealing, but encapsulation and tissue adhesions may hamper the safety and efficacy of LP retrieval. OBJECTIVE: We determined the incidence and cellular characteristics of tissue adherent to retrieved LPs and the potential implications for end-of-life strategy. METHODS: All 15 consecutive successful Nanostim LP retrievals in a tertiary center were included. We assessed the histopathology of adherent tissue and obtained clinical characteristics. RESULTS: Adherent tissue was present in 14 of 15 retrievals (93%; median implantation duration 36 months; range 0-96 months). The tissue consisted of fibrosis (n = 2), fibrosis and thrombus (n = 9), or thrombus only (n = 3). In short-term retrievals (<1 year), mostly fresh thrombi without fibrosis were seen. In later retrievals, the tissue consisted of fibrosis often with organizing or lytic thrombi. Fibrosis showed different stages of organization, notably early fibrocellular and later fibrosclerotic tissue. Inflammatory cells were seen (n = 4) without signs of infection. Tricuspid valve material was retrieved in 1 patient after 36 months, resulting in increased tricuspid regurgitation. CONCLUSION: Our results suggest that fibrosis and thrombus adherent to LPs are common and encapsulate the LP as seen in transvenous pacemakers. LPs may adhere to the tricuspid valve or subvalvular apparatus affecting retrieval safety. The end-of-life strategy should be optimized by incorporating risk stratification for excessive fibrotic encapsulation and adhesions.


Subject(s)
Device Removal/methods , Long Term Adverse Effects/pathology , Pacemaker, Artificial , Reoperation , Tissue Adhesions , Tricuspid Valve , Aged, 80 and over , Bradycardia/therapy , Equipment Failure Analysis , Female , Histological Techniques , Humans , Male , Outcome Assessment, Health Care , Pacemaker, Artificial/adverse effects , Pacemaker, Artificial/statistics & numerical data , Prosthesis Implantation/adverse effects , Prosthesis Implantation/instrumentation , Prosthesis Implantation/methods , Reoperation/adverse effects , Reoperation/instrumentation , Reoperation/methods , Tissue Adhesions/etiology , Tissue Adhesions/pathology , Tricuspid Valve/diagnostic imaging , Tricuspid Valve/pathology , Tricuspid Valve/physiopathology
4.
Horm Metab Res ; 53(9): 594-601, 2021 Sep.
Article in English | MEDLINE | ID: mdl-34298566

ABSTRACT

The triglyceride-glucose (TyG) index, a recently proposed indicator for insulin resistance, has been related with cardiovascular risks. We aimed to summarize the association between TyG index and incidence of major adverse cardiovascular events (MACEs) in patients with acute coronary syndrome (ACS). Cohort studies demonstrating the association between TyG index and incidence of MACEs in ACS patients with multivariate adjusted analyses were identified by search of PubMed, Embase, and Web of Science databases. A random-effekt model incorporating the heterogeneity was applied to pool the results. Eight cohort studies with 19 611 participants were included. Results showed that compared to those with the lowest category of TyG index, ACS patients with the highest category of TyG index were independently associated with higher risk of MACEs [risk ratio (RR): 1.94, 95% confidence interval (CI): 1.47-2.56, I2=85%, p <0.001). Subgroup analyses showed consistent results in patients with ST-segment elevated myocardial infarction or non-ST segment elevated ACS, in patients with or without diabetes, and in patients after percutaneous coronary intervention. Results were consistent in studies with TyG index analyzed as continuous variable (RR for per standard deviation increment of TyG index: 1.59, 95% CI: 1.38-1.83, I2=24%, p <0.001). In conclusion, higher TyG index may be independently associated with higher incidence of MACEs in patients with ACS.


Subject(s)
Acute Coronary Syndrome/physiopathology , Blood Glucose/metabolism , Cardiovascular Diseases/epidemiology , Long Term Adverse Effects/epidemiology , Triglycerides/metabolism , Biomarkers , Cardiovascular Diseases/etiology , Cardiovascular Diseases/metabolism , Cardiovascular Diseases/pathology , Cohort Studies , Humans , Incidence , Long Term Adverse Effects/etiology , Long Term Adverse Effects/metabolism , Long Term Adverse Effects/pathology , Risk Factors
5.
Chest ; 159(6): e365-e370, 2021 06.
Article in English | MEDLINE | ID: mdl-34099151

ABSTRACT

Pleuroparenchymal fibroelastosis (PPFE) is a progressive and frequently fatal interstitial lung disease that involves the upper lobes. Although its cause remains unknown, the histopathologic evidence underlying PPFE bears striking resemblance to that of the pulmonary apical cap (PAC), a relatively common and benign entity. We describe the case of a patient with PAC that evolved into distinctly asymmetric PPFE over 6 years after unilateral surgical lung injury. Given the histologic similarity between these two conditions, we propose that these two entities underlie common biologic pathways of abnormal response to lung injury, with the presence of a PAC increasing susceptibility to the development of PPFE in the face of ongoing inflammatory insults. This case describes the histopathologic evolution of PAC to PPFE before and after an inciting injury.


Subject(s)
Intraoperative Complications , Lung Diseases, Interstitial , Lung Injury , Lung , Pulmonary Fibrosis , Aged , Biopsy/methods , Cachexia/diagnosis , Cachexia/etiology , Coronary Artery Bypass/adverse effects , Diagnosis, Differential , Disease Progression , Dyspnea/diagnosis , Dyspnea/etiology , Fatal Outcome , Humans , Intraoperative Complications/pathology , Intraoperative Complications/physiopathology , Long Term Adverse Effects/pathology , Long Term Adverse Effects/physiopathology , Lung/diagnostic imaging , Lung/pathology , Lung Diseases, Interstitial/etiology , Lung Diseases, Interstitial/pathology , Lung Diseases, Interstitial/physiopathology , Lung Injury/complications , Lung Injury/pathology , Lung Injury/physiopathology , Male , Pulmonary Fibrosis/etiology , Pulmonary Fibrosis/pathology , Pulmonary Fibrosis/physiopathology , Respiratory Function Tests/methods , Tomography, X-Ray Computed/methods
6.
Urol Oncol ; 39(8): 493.e9-493.e15, 2021 08.
Article in English | MEDLINE | ID: mdl-33353864

ABSTRACT

INTRODUCTION: Men diagnosed with localized prostate cancer must navigate a highly preference-sensitive decision between treatment options with varying adverse outcome profiles. We evaluated whether use of a decision support tool previously shown to decrease decisional conflict also impacted the secondary outcome of post-treatment decision regret. METHODS: Participants were randomized to receive personalized decision support via the Personal Patient Profile-Prostate or usual care prior to a final treatment decision. Symptoms were measured just before randomization and 6 months later; decision regret was measured at 6 months along with records review to ascertain treatment choices. Regression modeling explored associations between baseline variables including race and D`Amico risk, study group, and 6-month variables regret, choice, and symptoms. RESULTS: At 6 months, 287 of 392 (73%) men returned questionnaires of which 257 (89%) had made a treatment choice. Of that group, 201 of 257 (78%) completely answered the regret scale. Regret was not significantly different between participants randomized to the P3P intervention compared to the control group (P = 0.360). In univariate analyses, we found that Black men, men with hormonal symptoms, and men with bowel symptoms reported significantly higher decision regret (all P < 0.01). Significant interactions were detected between race and study group (intervention vs. usual care) in the multivariable model; use of the Personal Patient Profile-Prostate was associated with significantly decreased decisional regret among Black men (P = 0.037). Interactions between regret, symptoms and treatment revealed that (1) men choosing definitive treatment and reporting no hormonal symptoms reported lower regret compared to all others; and (2) men choosing active surveillance and reporting bowel symptoms had higher regret compared to all others. CONCLUSION: The Personal Patient Profile-Prostate decision support tool may be most beneficial in minimizing decisional regret for Black men considering treatment options for newly-diagnosed prostate cancer. TRIAL REGISTRATION: NCT01844999.


Subject(s)
Choice Behavior , Decision Making/physiology , Decision Support Techniques , Emotions/physiology , Long Term Adverse Effects/pathology , Prostatic Neoplasms/psychology , Prostatic Neoplasms/therapy , Combined Modality Therapy , Delivery of Health Care , Follow-Up Studies , Humans , Long Term Adverse Effects/etiology , Male , Prognosis , Surveys and Questionnaires
7.
Acta Oncol ; 58(4): 398-406, 2019 Apr.
Article in English | MEDLINE | ID: mdl-30638100

ABSTRACT

BACKGROUND: Oxaliplatin, combined with capecitabine (CAPOX) or infused 5-fluorouracil (FOLFOX), is standard of care in the adjuvant treatment of colorectal cancer (CRC). Prospective data on prevalence of oxaliplatin induced acute and long-term neuropathy in a real-life patient population and its effects on quality of life (QOL) and survival is limited, and scarce in CAPOX versus FOLFOX treated, especially in a subarctic climate. METHODS: One hundred forty-four adjuvant CRC patients (all 72 CAPOX cases and 72 matched FOLFOX controls) were analyzed regarding oxaliplatin induced sensory neuropathy, which was graded according to NCI-CTCAEv3.0. Ninety-two long-term survivors responded to the QOL (EORTC QLQ-C30) and Chemotherapy-Induced Peripheral Neuropathy (EORTC CIPN20) questionnaires and were interviewed regarding long-term neuropathy. RESULTS: Acute neurotoxicity was present in 94% (136/144) during adjuvant therapy and there was a significant association between acute neurotoxicity and long-term neuropathy (p < .001). Long-term neuropathy was present in 69% (grade 1/2/3/4 in 36/24/8/1%) at median 4.2 years. Neuropathy grades 2-4 did not influence global health status, but it was associated with decreased physical functioning (p = .031), decreased role functioning (p = .040), and more diarrhea (p = .021) in QLQ-C30 items. There were no differences in acute neurotoxicity, long-term neuropathy, or in QOL between CAPOX and FOLFOX treated. Neuropathy showed no pattern of variation according to starting and stopping month or treatment during winter. CONCLUSIONS: Neuropathy following oxaliplatin containing adjuvant chemotherapy is present in two-thirds, years after cessation, and impairs some QOL scales. There is no difference in severity of acute or long-term neuropathy between CAPOX and FOLFOX treated and QOL is similar. No seasonal variation in neuropathy was noted.


Subject(s)
Adenocarcinoma/drug therapy , Antineoplastic Combined Chemotherapy Protocols/adverse effects , Colorectal Neoplasms/drug therapy , Long Term Adverse Effects/chemically induced , Peripheral Nervous System Diseases/chemically induced , Quality of Life , Adenocarcinoma/pathology , Adult , Aged , Capecitabine/administration & dosage , Chemotherapy, Adjuvant , Colorectal Neoplasms/pathology , Female , Fluorouracil/administration & dosage , Follow-Up Studies , Humans , Leucovorin/administration & dosage , Long Term Adverse Effects/pathology , Male , Middle Aged , Neoplasm Staging , Oxaliplatin/administration & dosage , Peripheral Nervous System Diseases/pathology , Surveys and Questionnaires
8.
J Hepatol ; 70(3): 440-448, 2019 03.
Article in English | MEDLINE | ID: mdl-30389551

ABSTRACT

BACKGROUND & AIMS: Hepatocellular carcinoma (HCC) is a frequent complication of liver disease. When feasible, hepatic resection is the first-choice therapy. However, tumor recurrence complicates at least 2/3 hepatic resections at 5 years. Early recurrences are mainly tumor or treatment-related, but predictors of late recurrences are undefined. We aimed to evaluate the factors related to HCC recurrence after curative resection, with liver and spleen stiffness measurement (LSM and SSM) as markers of severity and duration of the underlying liver disease. METHODS: We enrolled patients with chronic liver disease and primary HCC suitable for hepatic resection. We followed up patients for at least 30 months or until HCC recurrence. We performed uni- and multivariate analyses to evaluate the predictive role of tumor characteristics, laboratory data, LSM and SSM for both early and late recurrence of HCC. RESULTS: We prospectively enrolled 175 patients. Early HCC recurrence at multivariate analysis was associated with viral etiology, HCC grading (3 or 4), resection margins <1 cm and being beyond the Milan criteria. HCC late recurrence at univariate analysis was associated with esophageal varices (hazard ratio [HR] 3.321, 95% CI 1.564-7.053), spleen length (HR 3.123, 95% CI 1.377-7.081), platelet/spleen length ratio if <909 (HR 2.170, 95% CI 1.026-4.587), LSM (HR 1.036, 95% CI 1.005-1.067), SSM (HR 1.046, 95% CI 1.020-1.073). HCC late recurrence at multivariate analysis was independently associated only with SSM (HR 1.046, CI 1.020-1.073). Late HCC recurrence-free survival was significantly different according to the SSM cut-off of 70 kPa (p = 0.0002). CONCLUSIONS: SSM seems to be the only predictor of late HCC recurrence, since it is directly correlated with the degree of liver disease and portal hypertension, both of which are involved in carcinogenesis. LAY SUMMARY: The main result of this study is that spleen stiffness measurement, evaluated by transient elastography, seems to be the only predictor of the late recurrence of hepatocellular carcinoma, defined as recurrence after 24 months from liver resection. Indeed, spleen stiffness measurement is directly correlated with the degree of liver disease and portal hypertension, which are both involved in carcinogenesis.


Subject(s)
Carcinoma, Hepatocellular , Elasticity Imaging Techniques/methods , Hepatectomy/adverse effects , Liver Cirrhosis , Liver Neoplasms , Liver/pathology , Neoplasm Recurrence, Local/diagnosis , Spleen/pathology , Area Under Curve , Carcinoma, Hepatocellular/diagnosis , Carcinoma, Hepatocellular/etiology , Carcinoma, Hepatocellular/surgery , Female , Hepatectomy/methods , Humans , Italy/epidemiology , Liver Cirrhosis/complications , Liver Cirrhosis/pathology , Liver Neoplasms/diagnosis , Liver Neoplasms/surgery , Long Term Adverse Effects/pathology , Male , Middle Aged , Predictive Value of Tests , Prognosis
9.
Eur J Heart Fail ; 21(3): 360-369, 2019 03.
Article in English | MEDLINE | ID: mdl-30592353

ABSTRACT

AIMS: Despite our prior report suggesting heart failure (HF) risk reduction from cardiac resynchronization therapy with defibrillator (CRT-D) in mild HF patients with higher left ventricular ejection fraction (LVEF > 30%), data on mortality benefit in this cohort are lacking. We aimed to assess long-term mortality benefit from CRT-D in mild HF patients by LVEF > 30%. METHODS AND RESULTS: Among 1274 patients with mild HF and left bundle branch block enrolled in MADIT-CRT, we analysed long-term effects of CRT-D vs. implantable cardioverter defibrillator (ICD) therapy only, and reverse remodelling to CRT-D (left ventricular end-systolic volume percent change ≥ median at 1 year), on all-cause mortality and HF for the LVEF ≤ 30% and LVEF > 30 subgroups using Kaplan-Meier and Cox analyses. During long-term follow-up, CRT-D vs. ICD was associated with reduction in all-cause mortality in both patients with LVEF > 30% and LVEF ≤ 30% [hazard ratio (HR) 0.47, 95% confidence interval (CI) 0.25-0.85, P = 0.036 vs. HR 0.69, 95% CI 0.49-0.98, P = 0.013, interaction P = 0.261]. The efficacy of CRT-D vs. ICD only to reduce HF was similar in those with LVEF above and below 30% (HR 0.36, 95% CI 0.35-0.61, P < 0.001 vs. HR 0.46, 95% CI 0.35-0.61, P < 0.001; interaction P = 0.342). Patients with CRT-D-induced reverse remodelling had significant mortality reduction when compared to ICD, with either LVEF > 30% or LVEF ≤ 30% (HR 0.17 and 0.39), but no mortality benefit was seen in patients with less reverse remodelling. HF events, however, were reduced in both CRT-D-induced high and low reverse remodelling vs. ICD only, in both LVEF subgroups. CONCLUSIONS: In MADIT-CRT, left bundle branch block patients with higher LVEF (> 30%) derive long-term mortality benefit from CRT-D when exhibiting significant reverse remodelling. CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov ID NCT00180271, NCT01294449, and NCT02060110.


Subject(s)
Cardiac Resynchronization Therapy , Heart Failure , Long Term Adverse Effects , Stroke Volume , Ventricular Remodeling , Aged , Bundle-Branch Block/diagnosis , Bundle-Branch Block/etiology , Cardiac Resynchronization Therapy/methods , Cardiac Resynchronization Therapy/statistics & numerical data , Defibrillators, Implantable , Female , Heart Failure/mortality , Heart Failure/physiopathology , Heart Failure/therapy , Humans , Kaplan-Meier Estimate , Long Term Adverse Effects/etiology , Long Term Adverse Effects/mortality , Long Term Adverse Effects/pathology , Male , Middle Aged , Risk Factors , Treatment Outcome
10.
Can J Cardiol ; 34(6): 812.e1-812.e3, 2018 06.
Article in English | MEDLINE | ID: mdl-29801747

ABSTRACT

A 60-year-old man was diagnosed with melanoma. After receiving 13 infusions of nivolumab, he had fulminant myocarditis. The myocardial biopsy specimen revealed extensive lymphocytic infiltration, interstitial edema, and myocardial necrosis, with predominant CD4+, CD8+, CD20-, and programmed death-1- markers. Programmed death-1 ligand 1 (PD-L1) was predominantly expressed on the surface of the damaged myocardium. Although it is reported that myocarditis induced by the human anti-programmed death-1 inhibitor nivolumab therapy rarely occurred at > 2 months use in clinical trials, this case showed that even if at a late phase, long-term use of immune checkpoint inhibitors might to lead immune-related adverse events including myocarditis.


Subject(s)
B7-H1 Antigen/analysis , Immunoglobulins, Intravenous/administration & dosage , Intra-Aortic Balloon Pumping/methods , Melanoma/drug therapy , Myocarditis , Myocardium/pathology , Nivolumab , Prednisolone/administration & dosage , Antineoplastic Agents, Immunological/administration & dosage , Antineoplastic Agents, Immunological/adverse effects , Glucocorticoids/administration & dosage , Humans , Long Term Adverse Effects/chemically induced , Long Term Adverse Effects/pathology , Long Term Adverse Effects/physiopathology , Long Term Adverse Effects/therapy , Male , Melanoma/diagnosis , Middle Aged , Myocarditis/chemically induced , Myocarditis/pathology , Myocarditis/physiopathology , Myocarditis/therapy , Nivolumab/administration & dosage , Nivolumab/adverse effects , Programmed Cell Death 1 Receptor/antagonists & inhibitors , Pulse Therapy, Drug/methods , Treatment Outcome
11.
Medicine (Baltimore) ; 97(20): e10754, 2018 May.
Article in English | MEDLINE | ID: mdl-29768356

ABSTRACT

RATIONALE: Metastases of breast carcinoma to the main bronchus and choroid are rare, but have been reported in relevant literature. Late distant recurrence of breast carcinoma after more than 20 years is extremely rare. Herein, we report a 57-year-old woman with late distant recurrence and metastasis to the main bronchus and choroid almost 28 years after surgery. PATIENT CONCERNS: At the age of 29, the patient underwent chemotherapy and endocrine treatment after a right side mastectomy to remove breast carcinoma. The patient was hospitalized for a cough with blood-tinged sputum, dysphagia, and blurred vision in the left eye at the age of 57. DIAGNOSES: On evaluation, laboratory findings detected the elevated serum tumor markers of CA12-5, CA15-3, NSE, and Cyfra21-1. The imaging showed left lung metastase, multiple lymph node metastases, and small suspected metastases in the both sides of parietal lobes. Fundus fluorescein angiography showed choroidal occupying lesion of the left side which indicates secondary metastasis and retinal detachment. Combined with the pathological finding via fiberoptic bronchoscopic biopsy, the patient was clinically diagnosed with a late distant recurrence of breast carcinoma. INTERVENTIONS: The patient received oral endocrine therapy of letrozole, but she refused chemotherapy, radiotherapy and other topical treatments. OUTCOMES: At the 3-month follow-up visit, the multiple lesions of the left lung and lymph nodes had partially regressed, and the lesion of right parietal lobe had disappeared. The patient's clinical symptoms, such as blood-tinged sputum and dysphagia, had significantly improved. LESSONS: We have described this case and reviewed the relevant literature concerning late distant recurrence of breast carcinoma. Importantly, this case indicates that patients with HR positive breast carcinoma are more likely to develop late distant recurrence and clinicians should not ignore the follow-up examinations even more than 20 years after the surgery.


Subject(s)
Breast Neoplasms , Bronchial Neoplasms , Choroid Neoplasms , Long Term Adverse Effects , Mastectomy/adverse effects , Nitriles/administration & dosage , Triazoles/administration & dosage , Antineoplastic Agents/administration & dosage , Aromatase Inhibitors/administration & dosage , Biopsy/methods , Breast Neoplasms/pathology , Breast Neoplasms/surgery , Bronchi/diagnostic imaging , Bronchi/pathology , Bronchial Neoplasms/pathology , Bronchial Neoplasms/secondary , Bronchoscopy/methods , Choroid/diagnostic imaging , Choroid/pathology , Choroid Neoplasms/pathology , Choroid Neoplasms/secondary , Female , Fluorescein Angiography/methods , Humans , Letrozole , Long Term Adverse Effects/drug therapy , Long Term Adverse Effects/pathology , Lymphatic Metastasis/pathology , Mastectomy/methods , Middle Aged , Receptors, Estrogen/analysis , Receptors, Estrogen/antagonists & inhibitors , Treatment Outcome
12.
J Hepatol ; 69(3): 626-634, 2018 09.
Article in English | MEDLINE | ID: mdl-29709679

ABSTRACT

BACKGROUND & AIMS: Subclinical inflammatory changes are commonly described in long-term transplant recipients undergoing protocol liver biopsies. The pathogenesis of these lesions remains unclear. The aim of this study was to identify the key molecular pathways driving progressive subclinical inflammatory liver allograft damage. METHODS: All liver recipients followed at Hospital Clínic Barcelona who were >10 years post-transplant were screened for participation in the study. Patients with recurrence of underlying liver disease, biliary or vascular complications, chronic rejection, and abnormal liver function tests were excluded. Sixty-seven patients agreed to participate and underwent blood and serological tests, transient elastography and a liver biopsy. Transcriptome profiling was performed on RNA extracted from 49 out of the 67 biopsies employing a whole genome next generation sequencing platform. Patients were followed for a median of 6.8 years following the index liver biopsy. RESULTS: Median time since transplantation to liver biopsy was 13 years (10-22). The most frequently observed histological abnormality was portal inflammation with different degrees of fibrosis, present in 45 biopsies (67%). Two modules of 102 and 425 co-expressed genes were significantly correlated with portal inflammation, interface hepatitis and portal fibrosis. These modules were enriched in molecular pathways known to be associated with T cell mediated rejection. Liver allografts showing the highest expression levels for the two modules recapitulated the transcriptional profile of biopsies with clinically apparent rejection and developed progressive damage over time, as assessed by non-invasive markers of fibrosis. CONCLUSIONS: A large proportion of adult liver transplant recipients who survive long-term exhibit subclinical histological abnormalities. The transcriptomic profile of these patients' liver tissue closely resembles that of T cell mediated rejection and may result in progressive allograft damage. LAY SUMMARY: A large proportion of adult liver transplant recipients who survive for a long time exhibit subclinical histological abnormalities. The expression profile (a measurement of the activity of genes) of liver tissue from a large fraction of these patients closely resembles the profile of T cell mediated rejection. Liver allografts showing the highest expression levels of rejection-related genes developed progressive damage over time.


Subject(s)
Gene Expression Profiling/methods , Graft Rejection , Inflammation , Liver Transplantation , Liver , Long Term Adverse Effects , T-Lymphocytes , Adult , Asymptomatic Diseases , Biopsy/methods , Correlation of Data , Disease Progression , Female , Fibrosis/immunology , Fibrosis/pathology , Graft Rejection/etiology , Graft Rejection/pathology , Humans , Inflammation/immunology , Inflammation/pathology , Liver/immunology , Liver/pathology , Liver Function Tests/methods , Liver Transplantation/adverse effects , Liver Transplantation/methods , Long Term Adverse Effects/immunology , Long Term Adverse Effects/pathology , Male , Middle Aged , T-Lymphocytes/immunology , T-Lymphocytes/pathology
13.
Andrology ; 6(1): 136-141, 2018 01.
Article in English | MEDLINE | ID: mdl-29195014

ABSTRACT

Neglected side effects after radical prostatectomy have been previously reported. In this context, the prevalence of penile morphometric alterations has never been assessed in robot-assisted radical prostatectomy series. We aimed to assess prevalence of and predictors of penile morphometric alterations (i.e. penile shortening or penile morphometric deformation) at long-term follow-up in patients submitted to either robot-assisted (robot-assisted radical prostatectomy) or open radical prostatectomy. Sexually active patients after either robot-assisted radical prostatectomy or open radical prostatectomy prospectively completed a 28-item questionnaire, with sensitive issues regarding sexual function, namely orgasmic functioning, climacturia and changes in morphometric characteristics of the penis. Only patients with a post-operative follow-up ≥ 24 months were included. Patients submitted to either adjuvant or salvage therapies or those who refused to comprehensively complete the questionnaire were excluded from the analyses. A propensity-score matching analysis was implemented to control for baseline differences between groups. Logistic regression models tested potential predictors of penile morphometric alterations at long-term post-operative follow-up. Overall, 67 (50%) and 67 (50%) patients were included after open radical prostatectomy or robot-assisted radical prostatectomy, respectively. Self-rated post-operative penile shortening and penile morphometric deformation were reported by 75 (56%) and 29 (22.8%) patients, respectively. Rates of penile shortening and penile morphometric deformation were not different after open radical prostatectomy and robot-assisted radical prostatectomy [all p > 0.5]. At univariable analysis, self-reported penile morphometric alterations (either penile shortening or penile morphometric deformation) were significantly associated with baseline international index of erectile function-erectile function scores, body mass index, post-operative erectile function recovery, year of surgery and type of surgery (all p < 0.05). At multivariable analysis, robot-assisted radical prostatectomy was independently associated with a lower risk of post-operative penile morphometric alterations (OR: 0.38; 95% CI: 0.16-0.93). Self-perceived penile morphometric alterations were reported in one of two patients after radical prostatectomy at long-term follow-up, with open surgery associated with a potential higher risk of this self-perception.


Subject(s)
Long Term Adverse Effects/pathology , Penis/pathology , Postoperative Complications/pathology , Prostatectomy/adverse effects , Prostatectomy/methods , Aged , Humans , Long Term Adverse Effects/epidemiology , Long Term Adverse Effects/etiology , Male , Middle Aged , Postoperative Complications/epidemiology , Robotic Surgical Procedures/adverse effects
14.
Dis Esophagus ; 31(1): 1-6, 2018 Jan 01.
Article in English | MEDLINE | ID: mdl-29036607

ABSTRACT

Gastroesophageal reflux is a common problem following esophagectomy and reconstruction with gastric interposition. Despite a routine prescription of proton pump inhibitors, reflux-associated mucosal damage in the remnant esophagus is frequently observed. Purpose of this study is to evaluate mucosal damage in the esophageal remnant during long-term follow-up and to compare the prevalence of this damage between the subgroups of esophageal squamous cell and adenocarcinoma. All patients undergoing transthoracic Ivor-Lewis esophagectomy were prospectively entered in our IRB approved database. All patients underwent a routine check-up program with yearly surveillance endoscopies following esophagectomy. Only patients with a complete follow-up were included into this study. Endoscopic and histopathologic mucosal changes of the remnant esophagus were analyzed in close intervals. A total of 50 patients met the inclusion criteria, consisting of 31 adenocarcinomas (AC) and 19 squamous cell carcinomas (SCC). Mucosal damage was already seen 1 year after surgery in 20 patients macroscopically (43%) and in 21 patients microscopically (45%). At 5-year follow-up the prevalence for macroscopic and microscopic damage was 55% and 60%, respectively. The prevalence of mucosal damage was higher in AC patients than in SCC patients (1y-FU: 51% [AC] vs. 28% [SCC]; 5y-FU: 68% [AC] vs. 35% [SCC], P < 0.05). Newly acquired Barrett's esophagus was seen in 10 patients (20%) with two of those patients (20%) showing histopathologic proof of neoplasia. This study shows a high prevalence of reflux-associated mucosal damage in the remnant esophagus one year out of surgery and only a moderate increase in prevalence in the following years. Mucosal damage was more frequently seen in AC patients and the occurrence of de-novo Barrett's esophagus and de-novo neoplasia was high. Endoscopic surveillance with targeted biopsies seems to be an indispensable tool to follow patients after esophagectomy appropriately.


Subject(s)
Esophageal Neoplasms/surgery , Esophagectomy/adverse effects , Gastroesophageal Reflux/pathology , Long Term Adverse Effects/pathology , Postoperative Complications/pathology , Adenocarcinoma/surgery , Aged , Aged, 80 and over , Carcinoma, Squamous Cell/surgery , Esophageal Mucosa/pathology , Esophageal Mucosa/surgery , Esophagectomy/methods , Female , Follow-Up Studies , Gastroesophageal Reflux/etiology , Humans , Long Term Adverse Effects/etiology , Male , Middle Aged , Postoperative Complications/etiology , Prospective Studies , Retrospective Studies
16.
Acta Orthop Traumatol Turc ; 51(6): 495-498, 2017 Dec.
Article in English | MEDLINE | ID: mdl-28479128

ABSTRACT

Calcific periarthritis in the distal femur is a rare condition. Forty two year old Asian male visited to the outpatient clinic of orthopedic department with acute excruciating knee pain. The arthroscopic posterior cruciate ligament (PCL) reconstruction was performed 20 years ago with the bonepatellar tendon-bone (BPTB) autograft combined with Trevira (polyethylene terephthalate) artificial ligament. Severe tenderness was noted incidentally over the medial epicondyle area of the distal femur which the cancellous screw was inserted for PCL reconstruction, without any preceding trauma history or medial joint line tenderness due to degenerative change. The poorly defined calcific deposition was found in plain radiograph. The arthroscopic debridement of the calcification and screw removal from the distal femur was performed due to resist to conservative treatment with analgesics. After operation, the symptoms were resolved completely. The arthroscopic debridement of calcific periarthritis should be considered in specific cases, such as refractory cases with conservative management during 4-6 weeks. We present the arthroscopic treatment of the symptomatic calcific periarthritis on distal femur after PCL reconstruction can be effective.


Subject(s)
Arthralgia , Arthroscopy/methods , Knee Joint , Long Term Adverse Effects , Ossification, Heterotopic , Periarthritis , Posterior Cruciate Ligament Reconstruction/adverse effects , Adult , Arthralgia/diagnosis , Arthralgia/etiology , Bone Screws , Humans , Knee Joint/diagnostic imaging , Knee Joint/physiopathology , Knee Joint/surgery , Long Term Adverse Effects/etiology , Long Term Adverse Effects/pathology , Long Term Adverse Effects/physiopathology , Long Term Adverse Effects/surgery , Male , Ossification, Heterotopic/complications , Ossification, Heterotopic/diagnosis , Periarthritis/etiology , Periarthritis/pathology , Periarthritis/physiopathology , Periarthritis/surgery , Posterior Cruciate Ligament/pathology , Posterior Cruciate Ligament/surgery , Radiography/methods , Treatment Outcome
19.
Pediatr Rheumatol Online J ; 14(1): 58, 2016 Nov 10.
Article in English | MEDLINE | ID: mdl-27832795

ABSTRACT

BACKGROUND: Rheumatic diseases are associated with an increased fracture risk. The tissue level characteristics of the bone involvement in children have not been well elucidated. Our objectives were to describe the bone micro-architectural characteristics in children with rheumatic diseases on chronic glucocorticoids, and to determine associations between micro-architectural findings with clinical and radiological variables. METHODS: Children on chronic glucocorticoids for an underlying rheumatic disease were referred for evaluation of bone fragility given the presence of vertebral compression fractures. A trans-iliac bone biopsy was performed as part of the clinical assessment. Histomorphometric analysis and quantitative backscattered electron imaging (qBSE) of the biopsy samples were undertaken. RESULTS: Data of 15 children (14.0 ± 3.2 years) with a duration of glucocorticoid exposure of 6.2 ± 4.1 years and average prednisone dose of 14.1 ± 6.2 mg/m2/day were assessed. Histomorphometric analyses demonstrated significant decrease in trabecular thickness (p = 0.01), osteoid thickness (p < 0.01), osteoblast surface (p = 0.02) and increase in trabecular separation (p = 0.04) compared to published age-matched normative data. Severity of the trabecular deficit was correlated to glucocorticoid dose, height and body mass index Z score, but not bone mineral density or measures of disease activity. Using qBSE to measure bone mineralization, the subjects were shown to have a heterogeneous and hypermineralized profile, with higher cumulative glucocorticoid dose being associated with greater mineralization (p < 0.01). CONCLUSIONS: In children with rheumatic diseases presenting with vertebral fractures, there is evidence of abnormal bone matrix mineralization and impairments of bone micro-architecture that correlate to glucocorticoid dose.


Subject(s)
Glucocorticoids , Long Term Adverse Effects , Osteoporosis/prevention & control , Rheumatic Diseases , Spinal Fractures/prevention & control , Absorptiometry, Photon/methods , Adolescent , Biopsy/methods , Bone Density/drug effects , Bone and Bones/drug effects , Bone and Bones/pathology , Canada , Child , Dose-Response Relationship, Drug , Female , Glucocorticoids/administration & dosage , Glucocorticoids/adverse effects , Humans , Long Term Adverse Effects/etiology , Long Term Adverse Effects/pathology , Long Term Adverse Effects/prevention & control , Male , Osteoporosis/etiology , Osteoporosis/pathology , Rheumatic Diseases/complications , Rheumatic Diseases/drug therapy , Rheumatic Diseases/pathology , Severity of Illness Index , Spinal Fractures/etiology , Spinal Fractures/pathology , Statistics as Topic
20.
Can J Cardiol ; 32(12): 1577.e15-1577.e17, 2016 12.
Article in English | MEDLINE | ID: mdl-27568503

ABSTRACT

Carcinoid tumours arising from the thymus are exceedingly rare, and cardiac metastases have not previously been described in the setting of a primary thymic carcinoid tumour. We present a patient with recurrence of a carcinoid tumour initially resected from the thymus 15 years earlier, with multiple cardiac metastases. These metastatic tumours were visualized using multiple imaging modalities, including computed tomography, transthoracic echocardiogram, magnetic resonance imaging, and octreotide scan. A subsequent biopsy confirmed recurrence of his carcinoid tumour. This case highlights the role of multimodality imaging for diagnosis and the need for continued long-term surveillance in these patients.


Subject(s)
Carcinoid Tumor , Dexamethasone/administration & dosage , Heart Neoplasms , Multimodal Imaging/methods , Neoplasm Recurrence, Local , Thymectomy/adverse effects , Thymus Neoplasms , Antineoplastic Agents, Hormonal/administration & dosage , Carcinoid Tumor/pathology , Carcinoid Tumor/surgery , Heart Neoplasms/diagnostic imaging , Heart Neoplasms/pathology , Heart Neoplasms/secondary , Humans , Long Term Adverse Effects/diagnosis , Long Term Adverse Effects/pathology , Male , Middle Aged , Neoplasm Recurrence, Local/diagnostic imaging , Neoplasm Recurrence, Local/pathology , Radiotherapy/methods , Thymectomy/methods , Thymus Neoplasms/pathology , Thymus Neoplasms/surgery , Treatment Outcome
SELECTION OF CITATIONS
SEARCH DETAIL
...